source
- Otsuka showcases kidney drug data; Pfizer cuts an AI dealVoyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off gen…BioPharma Dive · 1mo ago↗ source
- STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and moreEli Lilly is halving its originally planned investment in the production of weight loss syringes in Germany in response to a cost-cutting lawSTAT · 1mo ago↗ source
- Parabilis Medicines charts $413M IPO to back peptide pipelineParabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut. If the drug developer follows through with it…